Pertuzumab biosimilar - CinnaGen
Alternative Names: PertuzumabLatest Information Update: 05 Nov 2023
At a glance
- Originator CinnaGen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Dimerisation inhibitors; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer
Most Recent Events
- 24 Mar 2021 Phase-III development is ongoing Breast cancer (Combination therapy, Neoadjuvant therapy, Late-stage disease) in Iran (IRCT20150303021315N11)
- 27 May 2020 CinnaGen completes a phase III trial in Breast cancer in Iran (NCT04957212)
- 04 Mar 2020 CinnaGen completes a phase III trial in Breast cancer (Combination therapy, Neoadjuvant therapy, Late-stage disease) in Iran, before March 2020 (IV) (IRCT20150303021315N11)